Jacek Kądziela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jacek Kądziela has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Adam Witkowski
Department of Interventional Cardiology and Angiology, National Institute of Cardiology, 04-628 Warsaw, Poland
11 shared publications - Aleksander Prejbisz
Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland
11 shared publications - Andrzej Januszewicz
Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
8 shared publications Ilona Michałowska
Department of Radiology, National Institute of Cardiology, Warszawa, Poland
6 shared publicationsAndrzej Januszewicz
Department of Hypertension, National Institute of Cardiology, Warszawa, Poland
5 shared publications- Marcin Demkow
Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, 04-628 Warsaw, Poland
5 shared publications
Latest Publications
- Open Access
- 5 July 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 146 (1) , 69-72
Pregnancy and Spontaneous Coronary Artery Dissection: Lessons From Survivors and Nonsurvivors
- 5 July 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 146 (1) , 69-72
Open AccessPregnancy and Spontaneous Coronary Artery Dissection: Lessons From Survivors and Nonsurvivors
- Open Access
- 9 September 2016
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 74 (9) , 961-968
Effects of renal sympathetic denervation on blood pressure and glycaemic control in patients with true resistant hypertension: results of Polish Renal Denervation Registry (RDN-POL Registry)
Background and aim: The assessment of percutaneous renal sympathetic denervation (RDN) efficacy in patients with true-resistant hypertension (true-RH) in a newly established net of Polish centres (RDN-POL Registry). Methods and results: Forty-four patients with true-RH (23 men, mean age 52.3 years) with daytime systolic blood pressure (SBP) in ambulatory blood pressure monitoring (ABPM) ≥ 135 mm Hg, on ≥ three antihypertensive agents, including diuretic, underwent RDN and completed 12-month follow-up. Mean reductions of office SBP/diastolic blood pressure were –23.8/–10.0, –12.5/–4.6, and –12.6/–6.1 mm Hg at 3, 6, and 12 months, respectively (all significant except diastolic at 6 months). Diabetes was the only predictor of office SBP reduction at 6 months (OR 9.6, 95% CI 1.4–66.5, p < 0.05). Mean 24-h SBP change was –8.3 mm Hg at 6 months and –4.6 mm Hg at 12 months. Increased 2 h-glucose in oral glucose tolerance test was the only predictor of 24-h SBP reduction at 6 months (OR 1.24 for 10 mg/dL glucose increase, 95% CI 1.04–1.48, p < 0.05). At 12 months, 24-h SBP change predictors were: baseline office SBP (OR 4.93 for 10 mm Hg SBP increment, 95% CI 1.01–24.1, p < 0.05) and 2 h-glucose (OR 1.47, 95% CI 1.08–2.00, p < 0.05). In ABPM responders, significant reduction of 2 h glucose was found as compared to the non-responders (–45.8 vs. –7.7 mg/dL, p < 0.005). Conclusions: The RDN-POL Registry demonstrated moderate blood pressure decrease after RDN. The predictors of blood pressure reduction were diabetes, 2 h-glucose, and baseline office SBP. Analysis of ABPM responders indicates a probable positive impact of RDN on glycaemic control. Background and aim: The assessment of percutaneous renal sympathetic denervation (RDN) efficacy in patients with true-resistant hypertension (true-RH) in a newly established net of Polish centres (RDN-POL Registry). Methods and results: Forty-four patients with true-RH (23 men, mean age 52.3 years) with daytime systolic blood pressure (SBP) in ambulatory blood pressure monitoring (ABPM) ≥ 135 mm Hg, on ≥ three antihypertensive agents, including diuretic, underwent RDN and completed 12-month follow-up. Mean reductions of office SBP/diastolic blood pressure were –23.8/–10.0, –12.5/–4.6, and –12.6/–6.1 mm Hg at 3, 6, and 12 months, respectively (all significant except diastolic at 6 months). Diabetes was the only predictor of office SBP reduction at 6 months (OR 9.6, 95% CI 1.4–66.5, p < 0.05). Mean 24-h SBP change was –8.3 mm Hg at 6 months and –4.6 mm Hg at 12 months. Increased 2 h-glucose in oral glucose tolerance test was the only predictor of 24-h SBP reduction at 6 months (OR 1.24 for 10 mg/dL glucose increase, 95% CI 1.04–1.48, p < 0.05). At 12 months, 24-h SBP change predictors were: baseline office SBP (OR 4.93 for 10 mm Hg SBP increment, 95% CI 1.01–24.1, p < 0.05) and 2 h-glucose (OR 1.47, 95% CI 1.08–2.00, p < 0.05). In ABPM responders, significant reduction of 2 h glucose was found as compared to the non-responders (–45.8 vs. –7.7 mg/dL, p < 0.005). Conclusions: The RDN-POL Registry demonstrated moderate blood pressure decrease after RDN. The predictors of blood pressure reduction were diabetes, 2 h-glucose, and baseline office SBP. Analysis of ABPM responders indicates a probable positive impact of RDN on glycaemic control.
- 9 September 2016
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 74 (9) , 961-968
Open AccessEffects of renal sympathetic denervation on blood pressure and glycaemic control in patients with true resistant hypertension: results of Polish Renal Denervation Registry (RDN-POL Registry)
Background and aim: The assessment of percutaneous renal sympathetic denervation (RDN) efficacy in patients with true-resistant hypertension (true-RH) in a newly established net of Polish centres (RDN-POL Registry). Methods and results: Forty-four patients with true-RH (23 men, mean age 52.3 years) with daytime systolic blood pressure (SBP) in ambulatory blood pressure monitoring (ABPM) ≥ 135 mm Hg, on ≥ three antihypertensive agents, including diuretic, underwent RDN and completed 12-month follow-up. Mean reductions of office SBP/diastolic blood pressure were –23.8/–10.0, –12.5/–4.6, and –12.6/–6.1 mm Hg at 3, 6, and 12 months, respectively (all significant except diastolic at 6 months). Diabetes was the only predictor of office SBP reduction at 6 months (OR 9.6, 95% CI 1.4–66.5, p < 0.05). Mean 24-h SBP change was –8.3 mm Hg at 6 months and –4.6 mm Hg at 12 months. Increased 2 h-glucose in oral glucose tolerance test was the only predictor of 24-h SBP reduction at 6 months (OR 1.24 for 10 mg/dL glucose increase, 95% CI 1.04–1.48, p < 0.05). At 12 months, 24-h SBP change predictors were: baseline office SBP (OR 4.93 for 10 mm Hg SBP increment, 95% CI 1.01–24.1, p < 0.05) and 2 h-glucose (OR 1.47, 95% CI 1.08–2.00, p < 0.05). In ABPM responders, significant reduction of 2 h glucose was found as compared to the non-responders (–45.8 vs. –7.7 mg/dL, p < 0.005). Conclusions: The RDN-POL Registry demonstrated moderate blood pressure decrease after RDN. The predictors of blood pressure reduction were diabetes, 2 h-glucose, and baseline office SBP. Analysis of ABPM responders indicates a probable positive impact of RDN on glycaemic control. Background and aim: The assessment of percutaneous renal sympathetic denervation (RDN) efficacy in patients with true-resistant hypertension (true-RH) in a newly established net of Polish centres (RDN-POL Registry). Methods and results: Forty-four patients with true-RH (23 men, mean age 52.3 years) with daytime systolic blood pressure (SBP) in ambulatory blood pressure monitoring (ABPM) ≥ 135 mm Hg, on ≥ three antihypertensive agents, including diuretic, underwent RDN and completed 12-month follow-up. Mean reductions of office SBP/diastolic blood pressure were –23.8/–10.0, –12.5/–4.6, and –12.6/–6.1 mm Hg at 3, 6, and 12 months, respectively (all significant except diastolic at 6 months). Diabetes was the only predictor of office SBP reduction at 6 months (OR 9.6, 95% CI 1.4–66.5, p < 0.05). Mean 24-h SBP change was –8.3 mm Hg at 6 months and –4.6 mm Hg at 12 months. Increased 2 h-glucose in oral glucose tolerance test was the only predictor of 24-h SBP reduction at 6 months (OR 1.24 for 10 mg/dL glucose increase, 95% CI 1.04–1.48, p < 0.05). At 12 months, 24-h SBP change predictors were: baseline office SBP (OR 4.93 for 10 mm Hg SBP increment, 95% CI 1.01–24.1, p < 0.05) and 2 h-glucose (OR 1.47, 95% CI 1.08–2.00, p < 0.05). In ABPM responders, significant reduction of 2 h glucose was found as compared to the non-responders (–45.8 vs. –7.7 mg/dL, p < 0.005). Conclusions: The RDN-POL Registry demonstrated moderate blood pressure decrease after RDN. The predictors of blood pressure reduction were diabetes, 2 h-glucose, and baseline office SBP. Analysis of ABPM responders indicates a probable positive impact of RDN on glycaemic control.
- 16 October 2014
- Published by Springer Nature
- p. 197-201
Obstructive Sleep Apnea
- Open Access
- 9 June 2014
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 21 (3) , 330
Authors’ response
- 9 June 2014
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 21 (3) , 330
Open AccessAuthors’ response
- Open Access
- 26 July 2013
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 20 (4) , 418-422
Prognostic value of renal fractional flow reserve in blood pressure response after renal artery stenting (PREFER study)
Background: The aim of our study was to determine a potential relationship between resting translesional pressures ratio (Pd/Pa ratio), renal fractional flow reserve (rFFR) and blood pressure response after renal artery stenting. Methods: Thirty five hypertensive patients (49% males, mean age 64 years) with at least 60% stenosis in angiography, underwent renal artery stenting. Translesional systolic pressure gradient (TSPG), Pd/Pa ratio (the ratio of mean distal to lesion and mean proximal pressures) and hyperemic rFFR - after intrarenal administration of papaverine - were measured before stent implantation. Ambulatory blood pressure measurements (ABPM) were recorded before the procedure and after 6 months. The ABPM results were presented as blood pressure changes in subgroups of patients with normal (>= 0.9) vs. abnormal (= 0.8) vs. abnormal (<0.8) rFFR. Results: Median Pd/Pa ratio was 0.84 (interquartile range 0.79-0.91) and strongly correlated with TSPG (r = -0.89, p < 0.001), minimal lumen diameter (MLD; r = 0.53, p < 0.005) and diameter stenosis (DS; r = -0.51, p < 0.005). Median rFFR was 0.78 (0.72-0.82). Similarly, significant correlation between rFFR and TSPG (r = -0.86, p < 0.0001), as well as with MLD (r = 0.50, p < 0.005) and DS (r = -0.51, p < 0.005) was observed. Procedural success was obtained in all patients. Baseline Pd/Pa ratio and rFFR did not predict hypertension response after renal artery stenting. Median changes of 24-h systolic/diastolic blood pressure were comparable in patients with abnormal vs. normal Pd/Pa ratio (-4/-3 vs. 0/2 mm Hg; p = NS) and with abnormal vs. normal rFFR (-2/-1 vs. -2/-0.5 mm Hg, respectively). Conclusions: Physiological assessment of renal artery stenosis using Pd/Pa ratio and papaverine-induced renal fractional flow reserve did not predict hypertension response after renal artery stenting.
- 26 July 2013
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 20 (4) , 418-422
Open AccessPrognostic value of renal fractional flow reserve in blood pressure response after renal artery stenting (PREFER study)
Background: The aim of our study was to determine a potential relationship between resting translesional pressures ratio (Pd/Pa ratio), renal fractional flow reserve (rFFR) and blood pressure response after renal artery stenting. Methods: Thirty five hypertensive patients (49% males, mean age 64 years) with at least 60% stenosis in angiography, underwent renal artery stenting. Translesional systolic pressure gradient (TSPG), Pd/Pa ratio (the ratio of mean distal to lesion and mean proximal pressures) and hyperemic rFFR - after intrarenal administration of papaverine - were measured before stent implantation. Ambulatory blood pressure measurements (ABPM) were recorded before the procedure and after 6 months. The ABPM results were presented as blood pressure changes in subgroups of patients with normal (>= 0.9) vs. abnormal (= 0.8) vs. abnormal (<0.8) rFFR. Results: Median Pd/Pa ratio was 0.84 (interquartile range 0.79-0.91) and strongly correlated with TSPG (r = -0.89, p < 0.001), minimal lumen diameter (MLD; r = 0.53, p < 0.005) and diameter stenosis (DS; r = -0.51, p < 0.005). Median rFFR was 0.78 (0.72-0.82). Similarly, significant correlation between rFFR and TSPG (r = -0.86, p < 0.0001), as well as with MLD (r = 0.50, p < 0.005) and DS (r = -0.51, p < 0.005) was observed. Procedural success was obtained in all patients. Baseline Pd/Pa ratio and rFFR did not predict hypertension response after renal artery stenting. Median changes of 24-h systolic/diastolic blood pressure were comparable in patients with abnormal vs. normal Pd/Pa ratio (-4/-3 vs. 0/2 mm Hg; p = NS) and with abnormal vs. normal rFFR (-2/-1 vs. -2/-0.5 mm Hg, respectively). Conclusions: Physiological assessment of renal artery stenosis using Pd/Pa ratio and papaverine-induced renal fractional flow reserve did not predict hypertension response after renal artery stenting.
- 1 January 2013
- Vol. 71 (1) , 63-5
[Mid-aortic syndrome in 18 year-old woman with arterial hypertension and bilateral renal artery stenosis].
Mid-aortic syndrome (MAS) is characterised by narrowing of the abdominal aorta, often with involvement of the renal and splanchnic arterial branches. Although uncommon, MAS is an important cause of renovascular hypertension in children and adolescents and should be considered in the differential diagnosis of hypertension . Hypertension is typically severe and often difficult to manage. The management of MAS should always be individualised and may include percutaneous transluminal renal angioplasty, stent implantation or surgical revascularisation. We present a 18 year-old woman with hypertension and MAS coexisting with bilateral renal artery stenosis who underwent left renal artery angioplasty and than was followed-up for one year.
- 1 January 2013
- Vol. 71 (1) , 63-5
[Mid-aortic syndrome in 18 year-old woman with arterial hypertension and bilateral renal artery stenosis].
Mid-aortic syndrome (MAS) is characterised by narrowing of the abdominal aorta, often with involvement of the renal and splanchnic arterial branches. Although uncommon, MAS is an important cause of renovascular hypertension in children and adolescents and should be considered in the differential diagnosis of hypertension . Hypertension is typically severe and often difficult to manage. The management of MAS should always be individualised and may include percutaneous transluminal renal angioplasty, stent implantation or surgical revascularisation. We present a 18 year-old woman with hypertension and MAS coexisting with bilateral renal artery stenosis who underwent left renal artery angioplasty and than was followed-up for one year.
- 1 January 2013
- Vol. 71 (1) , 72-6
[Hypertension caused by renal artery stenosis: new view on a difficult clinical problem].
- 1 January 2013
- Vol. 71 (1) , 72-6
[Hypertension caused by renal artery stenosis: new view on a difficult clinical problem].
- 1 January 2012
- Vol. 70 (4) , 398-400
[Late renal artery stent thrombosis treated with aspiration trombectomy in a patient with renal insufficiency and renal hypertension].
- 1 January 2012
- Vol. 70 (4) , 398-400
[Late renal artery stent thrombosis treated with aspiration trombectomy in a patient with renal insufficiency and renal hypertension].